Rowan T Chlebowski

Summary

Publications

  1. ncbi Bisphosphonates and breast cancer incidence and recurrence
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Breast Dis 33:93-101. 2011
  2. ncbi Bisphosphonates and breast cancer prevention
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, 1124 W Carson St Torrance, CA 90502, USA
    Anticancer Agents Med Chem 12:144-50. 2012
  3. pmc Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings
    Hiroyuki Katayama
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Fairview Avenue North, Seattle, WA 98109, USA
    Genome Med 1:47. 2009
  4. doi Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    JAMA 304:1684-92. 2010
  5. doi Prospective evaluation of two recruitment strategies for a randomized controlled cancer prevention trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, USA
    Clin Trials 7:744-8. 2010
  6. pmc Oral bisphosphonate use and breast cancer incidence in postmenopausal women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Clin Oncol 28:3582-90. 2010
  7. pmc Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, University of California Los Angeles, 1124 W Carson St, Torrance, CA 90502, USA
    J Clin Oncol 28:2690-7. 2010
  8. ncbi Early breast and prostate cancer and clinical outcomes (fracture)
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, California, USA
    Oncology (Williston Park) 23:16-20. 2009
  9. doi Menopausal hormone therapy, hormone receptor status, and lung cancer in women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Semin Oncol 36:566-71. 2009
  10. pmc Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Natl Cancer Inst 102:1413-21. 2010

Detail Information

Publications92

  1. ncbi Bisphosphonates and breast cancer incidence and recurrence
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Breast Dis 33:93-101. 2011
    ..Ongoing breast cancer adjuvant clinical trials are further evaluating bisphosphonates and, by their influence on contralateral cancers, may provide more evidence regarding the potential of bisphosphonates for breast cancer prevention...
  2. ncbi Bisphosphonates and breast cancer prevention
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, 1124 W Carson St Torrance, CA 90502, USA
    Anticancer Agents Med Chem 12:144-50. 2012
    ..Such reports require cautious interpretation because confounding by indication is an issue: bisphosphonates are prescribed for women with low bone mineral density, and women with low bone density are at decreased breast cancer risk...
  3. pmc Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings
    Hiroyuki Katayama
    Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Fairview Avenue North, Seattle, WA 98109, USA
    Genome Med 1:47. 2009
    ..CLINICAL TRIALS REGISTRATION : ClinicalTrials.gov identifier: NCT00000611...
  4. doi Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    JAMA 304:1684-92. 2010
    ..7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported...
  5. doi Prospective evaluation of two recruitment strategies for a randomized controlled cancer prevention trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, USA
    Clin Trials 7:744-8. 2010
    ..To evaluate two recruitment strategies used during the full-scale randomized, placebo-controlled Selenium and Vitamin E Cancer Prevention Trial (SELECT) at one clinical center...
  6. pmc Oral bisphosphonate use and breast cancer incidence in postmenopausal women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Clin Oncol 28:3582-90. 2010
    ..Emerging clinical evidence suggests intravenous bisphosphonates may inhibit breast cancer while oral bisphosphonates have received limited evaluation regarding breast cancer influence...
  7. pmc Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, University of California Los Angeles, 1124 W Carson St, Torrance, CA 90502, USA
    J Clin Oncol 28:2690-7. 2010
    ..625 mg/d) or placebo...
  8. ncbi Early breast and prostate cancer and clinical outcomes (fracture)
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, California, USA
    Oncology (Williston Park) 23:16-20. 2009
    ..Strategies for management of bone loss in breast and prostate cancer are outlined by guidelines from the American Society of Clinical Oncology and the National Comprehensive Cancer Network...
  9. doi Menopausal hormone therapy, hormone receptor status, and lung cancer in women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Semin Oncol 36:566-71. 2009
    ..In addition, the findings, together with ongoing studies evaluating estrogen receptor status and function, support further efforts to develop lung cancer intervention strategies targeting estrogen receptor expression...
  10. pmc Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Natl Cancer Inst 102:1413-21. 2010
    ..We conducted post hoc analyses in the WHI trial evaluating estrogen alone to determine whether use of conjugated equine estrogen without progestin had a similar adverse influence on lung cancer...
  11. pmc Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Lancet 374:1243-51. 2009
    ..To assess whether such an association exists, we undertook a post-hoc analysis of lung cancers diagnosed in the trial over the entire follow-up period...
  12. ncbi Breast cancer after use of estrogen plus progestin in postmenopausal women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    N Engl J Med 360:573-87. 2009
    ..Subsequently, the incidence of breast cancer also dropped, suggesting a cause-and-effect relation between hormone treatment and breast cancer. However, the cause of this decrease remains controversial...
  13. ncbi Predicting risk of breast cancer in postmenopausal women by hormone receptor status
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502, USA
    J Natl Cancer Inst 99:1695-705. 2007
    ..We evaluated and attempted to improve the performance of the Breast Cancer Risk Assessment Tool (i.e., the Gail model) for estimating invasive breast cancer risk by receptor status in postmenopausal women...
  14. doi Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Arch Intern Med 168:370-7; quiz 345. 2008
    ..The effect of combined hormone therapy on breast cancer detection is not established...
  15. doi Translating trial data into patients benefits: making the right choice
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson Street, Building J 3, Torrance, CA 90502, USA
    Breast 17:S9-15. 2008
    ..Therefore, using an AI at the earliest opportunity provides patients with the best option to prevent the recurrence and excess adverse events associated with tamoxifen...
  16. pmc Calcium plus vitamin D supplementation and the risk of breast cancer
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Natl Cancer Inst 100:1581-91. 2008
    ..Although some observational studies have associated higher calcium intake and especially higher vitamin D intake and 25-hydroxyvitamin D levels with lower breast cancer risk, no randomized trial has evaluated these relationships...
  17. doi Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial
    Rowan T Chlebowski
    Division of Medical Oncology and Hematology, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Clin Breast Cancer 8:343-6. 2008
    ....
  18. doi Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer
    Rowan T Chlebowski
    Division of Medical Oncology and Hematology, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Harbor UCLA Medical Center, 1000 W Carson Street, Torrance, CA 90502, USA
    Breast Cancer Res Treat 112:25-34. 2008
    ..Available evidence supports a hypothesis that upfront adjuvant AI therapy is the most appropriate treatment strategy for postmenopausal patients with HR+ disease. Definitive evidence awaits results from ongoing randomized trials...
  19. pmc 25-hydroxyvitamin D concentration, vitamin D intake and joint symptoms in postmenopausal women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, United States
    Maturitas 68:73-8. 2011
    ..However, the results are mixed and few studies have evaluated associations between 25(OH) D concentrations and both total vitamin D intake and clinical joint symptoms...
  20. pmc Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, 90502, USA
    J Natl Cancer Inst 105:526-35. 2013
    ..To address differences, a cohort of WHI observational study participants with characteristics similar to the WHI clinical trial was studied...
  21. pmc Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Menopause 20:600-8. 2013
    ..Against this background, estrogen-alone effects on joint symptoms were examined in post hoc analyses in the Women's Health Initiative randomized, placebo-controlled, clinical trial...
  22. ncbi Ethnicity and breast cancer: factors influencing differences in incidence and outcome
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Building J 3, Torrance, CA 90502, USA
    J Natl Cancer Inst 97:439-48. 2005
    ..The influence of breast cancer risk factors on these differences has received little attention...
  23. ncbi Estrogen plus progestin and colorectal cancer in postmenopausal women
    Rowan T Chlebowski
    Department of Medicine, Harbor UCLA Research and Education Institute, Torrance, Calif 90502, USA
    N Engl J Med 350:991-1004. 2004
    ..We analyzed features of the colorectal cancers that developed and their relation to the characteristics of the participants...
  24. pmc Changing concepts: Menopausal hormone therapy and breast cancer
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor, UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
    J Natl Cancer Inst 104:517-27. 2012
    ..Currently, the different effects of estrogen plus progestin vs estrogen alone on breast cancer are not completely understood...
  25. doi Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, CA 90502, USA
    Breast J 18:299-302. 2012
    ..Thus, aromatase inhibitors, and perhaps particularly exemestane, provide an option to address the risk of contralateral breast cancer in postmenopausal women with DCIS managed with mastectomy...
  26. ncbi Insulin, physical activity, and caloric intake in postmenopausal women: breast cancer implications
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA 90502, USA
    J Clin Oncol 22:4507-13. 2004
    ..However, there are few data on the relative contribution of physical activity, caloric intake, and BMI to fasting insulin levels...
  27. pmc Diabetes, metformin, and breast cancer in postmenopausal women
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Clin Oncol 30:2844-52. 2012
    ..Therefore, we assessed associations among diabetes, metformin use, and breast cancer in postmenopausal women participating in Women's Health Initiative clinical trials...
  28. ncbi Adherence to endocrine therapy for breast cancer
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA 90502 2064, USA
    Oncology 71:1-9. 2006
    ..Therefore, we reviewed the published literature regarding hormonal therapy adherence in clinical trial and practice settings...
  29. ncbi Nutrition and physical activity influence on breast cancer incidence and outcome
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Building J 3, Torrance, CA 90502, USA Electronic address
    Breast 22:S30-7. 2013
    ..To provide a current perspective on nutrition and physical activity influence on breast cancer...
  30. pmc Vitamin D intake and lung cancer risk in the Women's Health Initiative
    Ting Yuan David Cheng
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA and Biostatistics, University of Washington, Seattle, WA Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA
    Am J Clin Nutr 98:1002-11. 2013
    ..Prior research suggests that vitamin D protects against lung cancer only among certain subgroups...
  31. ncbi Bone health in women with early-stage breast cancer
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson St, Building J 3, Torrance, CA 90502, USA
    Clin Breast Cancer 5:S35-40. 2005
    ..Current information suggests bone loss associated with estrogen reduction in breast cancer survivors may represent a preventable and treatable condition. Ongoing clinical trials will definitively evaluate this hypothesis...
  32. doi Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer
    Karen W Kwan
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Clin Breast Cancer 9:219-24. 2009
    ....
  33. ncbi Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA 90502 2004, USA
    Clin Breast Cancer 6:S58-64. 2006
    ..If remaining issues are to be addressed, more rigorous CHD and stroke assessment procedures are needed in future trials evaluating AIs...
  34. pmc Vitamin D and breast cancer: interpreting current evidence
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 11243 West Carson Street, Torrance, CA 90502, USA
    Breast Cancer Res 13:217. 2011
    ..Current evidence supports the pursuit of several research questions but not routine 25-hydroxyvitamin D monitoring and vitamin D supplementation to reduce breast cancer incidence or improve breast cancer outcome...
  35. pmc Breast tenderness after initiation of conjugated equine estrogens and mammographic density change
    Carolyn J Crandall
    Department of Medicine, David Geffen School of Medicine at University of California, UCLA Medicine GIM, 911 Broxton Ave, 1st Floor, Los Angeles, CA 90024, USA
    Breast Cancer Res Treat 131:969-79. 2012
    ..4 vs. 0.6% at year 1, 2.2 vs. 1.0% at year 2, P = 0.30). The new-onset of breast tenderness after initiation of CEE + MPA, but not CEE alone, is associated with greater increases in mammographic density...
  36. doi Adherence to oral endocrine therapy for breast cancer: a nursing perspective
    Christine Miaskowski
    Department of Physiological Nursing, University of California, San Francisco, CA, USA
    Clin J Oncol Nurs 12:213-21. 2008
    ..This article summarizes the issues surrounding adherence, paying specific attention to adjuvant endocrine therapy for breast cancer, and outlines strategies to reduce nonadherence that nurses can incorporate into clinical practice...
  37. ncbi Alcohol and folate consumption and risk of benign proliferative epithelial disorders of the breast
    Yan Cui
    Office of Health Assessment and Epidemiology, Los Angeles County Department of Public Health, Los Angeles, CA, USA
    Int J Cancer 121:1346-51. 2007
    ..In conclusion, we observed that alcohol consumption and folate intake were not associated with altered risk of BPED, and that there was no effect modification between them in relation to the risk of BPED...
  38. ncbi Vitamin D and breast cancer incidence and outcome
    Rowan T Chlebowski
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 W Carson Street, Torrance, CA 90502, USA
    Anticancer Agents Med Chem 13:98-106. 2013
    ..However, a full-scale randomized trial evaluating the influence of vitamin D supplementation on breast cancer recurrence is likely not feasible...
  39. pmc Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials
    Carolyn J Crandall
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles UCLA Medicine GIM, 911 Broxton Avenue, 1st Floor, Los Angeles, CA 90024, USA
    Breast Cancer Res Treat 132:275-85. 2012
    ..The association of CEE + MPA therapy with increased breast cancer risk was especially pronounced among women with baseline breast tenderness...
  40. ncbi Menopausal hormone therapy after breast cancer
    Rowan T Chlebowski
    Harbor UCLA Research and Education Institute, Torrance, CA 90502, USA
    Lancet 363:410-1. 2004
  41. ncbi Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study
    Rowan T Chlebowski
    Department of Medicine, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, 1124 West Carson St, Building J 3, Torrance, CA 90502 2064, USA
    J Natl Cancer Inst 98:1767-76. 2006
    ..We carried out a randomized, prospective, multicenter clinical trial to test the effect of a dietary intervention designed to reduce fat intake in women with resected, early-stage breast cancer receiving conventional cancer management...
  42. doi Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis
    Shagufta Yasmeen
    University of California, Davis School of Medicine, Sacramento, California, USA
    Cancer 117:3252-61. 2011
    ..Interactions with comorbidity burden and comorbidity-related care have not been examined as potential explanations for racial/ethnic disparities in advanced-stage breast cancer at diagnosis...
  43. ncbi Research staff turnover and participant adherence in the Women's Health Initiative
    Marie Jackson
    Harbor UCLA Research and Education Institute, Torrance, California 90502 2064, USA
    Control Clin Trials 24:422-35. 2003
    ..Further prospective study exploring process evaluation of the provider side of controlled trial conduct is indicated...
  44. pmc Utility of two cancer organization websites for a multiethnic, public hospital oncology population: comparative cross-sectional survey
    Katherine D Nguyen
    Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    J Med Internet Res 7:e28. 2005
    ..While information websites have been developed by major cancer organizations, their appropriateness for patients in multiethnic, multilingual public hospital settings has received limited attention...
  45. ncbi HT and breast cancer risk
    Michelle L Geller
    Harbor UCLA Research and Education Institute, Torrance, CA 90502, USA
    Fertil Steril 80:5-9; quiz 54-5. 2003
    ....
  46. doi Walking speed, physical activity, and breast cancer in postmenopausal women
    Karen Kwan
    aDepartment of Medicine, Kaiser Foundation Hospital Sunset, Los Angeles bLos Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California cFred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, Washington dDepartment of Social and Prevention Medicine, School of Public Health and Health Professions, University of Buffalo, Buffalo eDepartment of Preventive Medicine, Stony Brook University School of Medicine, Stony Brook fDepartment of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, New York gDepartment of Medicine, George Washington University, Washington, District of Columbia hDepartment of Geriatric Medicine, John A Burns School of Medicine, University of Hawaii, Honolulu, Hawaii iDepartment of Behavioral Science, Yale School of Public Health, New Haven, Connecticut, USA
    Eur J Cancer Prev 23:49-52. 2014
    ..Our findings do not support use of timed walking speed as an objective surrogate for self-reported physical activity. ..
  47. ncbi Abnormal mammographic findings with short-interval follow-up recommendation
    Rowan T Chlebowski
    Department of Medicine, Division of Medical Oncology and Hematology, Los Angeles BioMedical Research Institute and Harbor University of California Los Angeles Medical Center, Torrance, CA 90502, USA
    Clin Breast Cancer 6:235-9. 2005
    ..Given the potential psychologic impact of abnormal mammographic results, studies attempting to more accurately relate screening mammography findings to breast cancer risk are a priority...
  48. ncbi Weight loss in breast cancer patient management
    Rowan T Chlebowski
    Harbor University of California Los Angeles Research and Education Institute, Torrance, CA 90502, USA
    J Clin Oncol 20:1128-43. 2002
    ..To systematically review and summarize evidence relevant to obesity and breast cancer clinical outcome, potential hormonal mediating mechanisms, and the current status of weight loss interventions for chronic disease management...
  49. pmc Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer
    Brigette L Tippin
    Division of Medical Genetics, Harbor UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA, USA
    Prostaglandins Other Lipid Mediat 97:22-8. 2012
    ..Other approaches will be needed to establish a role for HPGDS in occurrence of human intestinal tumors, as indicated by a mouse model...
  50. ncbi Management of bloody nipple discharge
    Hernan I Vargas
    Department of Surgery, Division of Surgical Oncology, Harbor UCLA Medical Center, 1000 W Carson Street, Box 25, Torrance, CA 90502, USA
    Curr Treat Options Oncol 3:157-61. 2002
    ..The early success reported with image-guided excision of papilloma and duct endoscopy promises a significant improvement in our diagnostic accuracy from minimally invasive emerging technology...
  51. ncbi Breast cancer risk reduction: strategies for women at increased risk
    Rowan T Chlebowski
    Harbor UCLA Research and Education Institute, 1124 W Carson Street, Torrance, California 90502 2064, USA
    Annu Rev Med 53:519-40. 2002
    ..Under active evaluation are novel SERMs, aromatase inhibitors/inactivators, gonadotrophin-releasing hormone agonists, retinoids, statins, and tyrosine kinase and cyclooxygenase-2 inhibitors...
  52. ncbi American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002
    Eric P Winer
    Health Services Research Department, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 20:3317-27. 2002
    ..POTENTIAL INTERVENTIONS: Anastrozole, letrozole, and exemestane...
  53. ncbi Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy
    Rowan T Chlebowski
    Harbor UCLA Research and Education Institute, Torrance 90502, USA
    Semin Oncol 30:776-88. 2003
    ....
  54. pmc Meta-analysis of vascular and neoplastic events associated with tamoxifen
    R Scott Braithwaite
    Section of Clinical Systems Modeling, Division of General Internal Medicine, Department of Medicne, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Gen Intern Med 18:937-47. 2003
    ..Our purpose was to estimate the effects of tamoxifen on potentially life-threatening vascular and neoplastic outcomes...
  55. ncbi American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004
    Eric P Winer
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 23:619-29. 2005
    ..To update the 2003 American Society of Clinical Oncology technology assessment on adjuvant use of aromatase inhibitors...
  56. ncbi Progestins and recurrence in breast cancer survivors
    Rowan T Chlebowski
    J Natl Cancer Inst 97:471-2. 2005
  57. ncbi Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer
    Francesmary Modugno
    Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, 516A Parran Hall, 130 DeSoto Street, Pittsburgh, PA 15261, USA
    Int J Cancer 118:1292-301. 2006
    ..Estrogen metabolism differs according to both BMI and HT use, potentially explaining the interaction between BMI and HT in relation to breast cancer risk...
  58. ncbi Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial
    Anne McTiernan
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98019, USA
    J Natl Cancer Inst 97:1366-76. 2005
    ..Increased mammographic density reduces the sensitivity of screening mammography, is associated with increased breast cancer risk, and may be hormone related. We assessed the effect of estrogen-plus-progestin therapy on mammographic density...
  59. ncbi Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative
    Randall E Harris
    The Ohio State University College of Medicine and Public Health, Columbus, Ohio 43210 1240, USA
    Cancer Res 63:6096-101. 2003
    ..Our results indicate that the regular use of aspirin, ibuprofen, or other NSAIDs may have a significant chemopreventive effect against the development of breast cancer and underscore the need for clinical trials to confirm this effect...
  60. pmc Body mass index and waist circumference in relation to lung cancer risk in the Women's Health Initiative
    Geoffrey C Kabat
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY 10461, USA
    Am J Epidemiol 168:158-69. 2008
    ..These findings suggest that in smokers, BMI is inversely associated with lung cancer risk and that waist circumference is positively associated with risk...
  61. ncbi Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial
    Rowan T Chlebowski
    Harbor UCLA Research and Education Institute, Torrance 90502, USA
    JAMA 289:3243-53. 2003
    ..Outstanding issues not previously addressed include characteristics of breast cancers observed among women using hormones and whether diagnosis may be influenced by hormone effects on mammography...
  62. ncbi American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting
    Eric P Winer
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 21:2597-9. 2003
  63. ncbi Frequency and predictive value of a mammographic recommendation for short-interval follow-up
    Shagufta Yasmeen
    University of California, Department of Obstetrics Gynecology and Internal Medicine, Davis, USA
    J Natl Cancer Inst 95:429-36. 2003
    ....
  64. ncbi Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States)
    Libby M Morimoto
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Cancer Causes Control 13:741-51. 2002
    ....
  65. ncbi Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model
    Nananda F Col
    Med Decis Making 22:386-93. 2002
    ..However, this benefit is modulated in women at increased endometrial cancer risk and depends on assumptions concerning tamoxifen's lingering effects on breast and endometrial cancer...
  66. ncbi American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition
    Rowan T Chlebowski
    Health Services Research Department, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 20:3328-43. 2002
    ..To update an evidence-based technology assessment of chemoprevention strategies for breast cancer risk reduction. POTENTIAL INTERVENTIONS: Tamoxifen, raloxifene, aromatase inhibition, and fenretinide...
  67. ncbi Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
    Ross L Prentice
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Wash 98109, USA
    JAMA 295:629-42. 2006
    ..The hypothesis that a low-fat dietary pattern can reduce breast cancer risk has existed for decades but has never been tested in a controlled intervention trial...
  68. pmc Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study
    Ross L Prentice
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Am J Epidemiol 167:1407-15. 2008
    ....
  69. ncbi Biological significance of interventions that change breast density
    Rowan T Chlebowski
    J Natl Cancer Inst 95:4-5. 2003
  70. doi Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis
    Rowan T Chlebowski
    J Natl Cancer Inst 100:1331-2; author reply 132-3. 2008
  71. doi Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution
    Rowan T Chlebowski
    J Natl Cancer Inst 100:1341-3. 2008
  72. ncbi Aromatase inhibitors and breast cancer treatment
    Rowan T Chlebowski
    JAMA 296:651; author reply 651. 2006
  73. doi Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial
    Thomas E Rohan
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA
    J Natl Cancer Inst 100:563-71. 2008
    ..We tested the effect of conjugated equine estrogen (CEE) on risk of benign proliferative breast disease in the Women's Health Initiative (WHI) randomized controlled trial...
  74. ncbi Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin
    Garnet L Anderson
    WHI Clinical Coordinating Center, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M3 A410, P O Box 19024, Seattle, WA 98109 1024, United States
    Maturitas 55:103-15. 2006
    ..To assess the extent to which prior hormone therapy modifies the breast cancer risk found with estrogen plus progestin (E+P) in the Women's Health Initiative (WHI) randomized trial...
  75. pmc Estrogen plus progestin therapy and breast cancer in recently postmenopausal women
    Ross L Prentice
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Am J Epidemiol 167:1207-16. 2008
    ..64 (95% confidence interval: 1.00, 2.68) over a 5-year period of use and 2.19 (95% confidence interval: 1.56, 3.08) over a 10-year period of use...
  76. doi Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin
    Gerardo Heiss
    University of North Carolina, School of Public Health, Department of Epidemiology, Chapel Hill, NC 27514 3628, USA
    JAMA 299:1036-45. 2008
    ..The Women's Health Initiative (WHI) trial of estrogen plus progestin vs placebo was stopped early, after a mean 5.6 years of follow-up, because the overall health risks of hormone therapy exceeded its benefits...
  77. ncbi Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy
    Marcia L Stefanick
    Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, Calif 94305, USA
    JAMA 295:1647-57. 2006
    ..Preliminary results suggesting possible reduction in breast cancers warranted more detailed analysis...
  78. ncbi Letrozole or tamoxifen in early breast cancer
    Rowan T Chlebowski
    N Engl J Med 354:1528-30; author reply 1528-30. 2006
  79. pmc Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial
    Ross L Prentice
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, PO Box 19024, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 99:1534-43. 2007
    ..The trial protocol also listed ovarian cancer and endometrial cancer as outcomes that may be favorably affected by the intervention...
  80. ncbi The decrease in breast-cancer incidence in 2003 in the United States
    Peter M Ravdin
    Department of Biostatistics, M D Anderson Cancer Center, Houston, USA
    N Engl J Med 356:1670-4. 2007
    ..The contributions of other causes to the change in incidence seem less likely to have played a major role but have not been excluded...
  81. pmc Estrogen plus progestin and risk of benign proliferative breast disease
    Thomas E Rohan
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Cancer Epidemiol Biomarkers Prev 17:2337-43. 2008
    ..76 (95% CI, 0.38-1.52). The risk varied little by levels of baseline characteristics. The results of this study suggest that the use of estrogen plus progestin may increase the risk of benign proliferative breast disease...
  82. ncbi Diet and breast cancer recurrence
    Rowan T Chlebowski
    JAMA 298:2135; author reply 2135-6. 2007
  83. ncbi Calcium plus vitamin D supplementation and the risk of fractures
    Rebecca D Jackson
    Division of Endocrinology, Ohio State University, 485 McCampbell, 1581 Dodd Dr, Columbus, OH 43210, USA
    N Engl J Med 354:669-83. 2006
    ..The efficacy of calcium with vitamin D supplementation for preventing hip and other fractures in healthy postmenopausal women remains equivocal...
  84. ncbi Re: Short-interval follow-up mammography: are we doing the right thing?
    Shagufta Yasmeen
    J Natl Cancer Inst 95:1175-6. 2003
  85. ncbi Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model
    Richard J Santen
    Department of Internal Medicine Endocrinology, University of Virginia Health System, Box 801416, Charlottesville, Virginia 22908, USA
    Endocr Relat Cancer 14:169-87. 2007
    ..The BCPCG analyzed potentially available clinical material from previous prospective studies and determined that a large case/control study to evaluate these new factors might be feasible at this time...
  86. ncbi Cigarette smoking and risk of benign proliferative epithelial disorders of the breast in the Women's Health Initiative
    Yan Cui
    Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Ave, Belfer 1301, Bronx, NY 10461, USA
    Cancer Causes Control 18:431-8. 2007
    ..To investigate the association between cigarette smoking and risk of benign proliferative epithelial disorders (BPED) of the breast...
  87. ncbi Obesity and early-stage breast cancer
    Rowan T Chlebowski
    J Clin Oncol 23:1345-7. 2005
  88. pmc Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence
    Nananda F Col
    Brown Medical School, Providence, Rhode Island, USA
    Breast Cancer Res 7:R535-40. 2005
    ..Our objectives were to estimate the effects of HT on recurrence in breast cancer survivors and to examine the reliability of these estimates...
  89. ncbi Statin use and breast cancer: prospective results from the Women's Health Initiative
    Jane A Cauley
    Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261, USA
    J Natl Cancer Inst 98:700-7. 2006
    ....
  90. ncbi Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
    Shirley A A Beresford
    Department of Epidemiology, University of Washington, Seattle, WA 98195 7236, USA
    JAMA 295:643-54. 2006
    ..Observational studies and polyp recurrence trials are not conclusive regarding the effects of a low-fat dietary pattern on risk of colorectal cancer, necessitating a primary prevention trial...
  91. ncbi Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
    Barbara V Howard
    MedStar Research Institute Howard University, Washington, DC, USA
    JAMA 295:655-66. 2006
    ..Multiple epidemiologic studies and some trials have linked diet with cardiovascular disease (CVD) prevention, but long-term intervention data are needed...
  92. ncbi American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
    Bruce E Hillner
    J Clin Oncol 21:4042-57. 2003
    ..To update the 2000 ASCO guidelines on the role of bisphosphonates in women with breast cancer and address the subject of bone health in these women...